METTL3 and hepatocellular carcinoma: Survival analysis showed that METTL3 serves as a prognostic factor for poor outcomes for CRC [121, 143], GC [117, 133], pancreatic cancer [124], HCC [122, 123] and thyroid carcinoma [128] patients.